|
|
 |
|
Viewing report
|
|
|
|
U.S. Market for X-Ray, Mammography and Contrast Agents 2010 (Executive Summary)
iData Research, Dec 2010, Pages: 9
In 2009, the U.S. market for X-ray, mammography and contrast agents was valued at over $5 billion. The medical imaging equipment market includes X-rays, mammography as well as contrast agents and injectors. The market declined in 2009 due to the deficit reduction act, which limited reimbursement for some imaging modalities. In addition, the global economic recession of 2008 to 2009 negatively impacted the market; however, the market is expected to recover beginning in 2010.
This market includes:
- Analog X-ray
- Computed Radiography X-ray
- Digital Radiography X-ray
- Fluoroscopy
- Cardiovascular X-ray
- Orthopedic X-ray
- Analog Mammography
- Computed Radiography Mammography
- Digital Radiography Mammography
- BSGI Mammography
- PEM Mammography
- X-Ray/CT Contrast Agents
- MRI Contrast Agents
- Ultrasound Contrast Agents
- Contrast Injector
Within the X-ray, mammography and contrast agent market, companies such as Bracco, Bayer Healthcare Pharmaceuticals, Covidien, Fujifilm, GE Healthcare, Philips Healthcare and Siemens Healthcare lead the market, among many others. This report provides a comprehensive and detailed analysis of market revenues by device type, market forecasts through 2016, unit sales, average selling prices, market drivers and limiters and a detailed competitive analysis, including manufacturer market shares and product portfolios.
This is an executive summary only. The full-report is also available for purchase.
Keywords:
imaging, x-ray, mammography, contrast agents, analog x-ray, computed radiography, digital radiography, fluoroscopy, cardiovascular, orthopedic, positron emission mammography
|
|
|
|
